北京人民解放军总医院（301医院）肿瘤中心、解放军总医院肿瘤中心
Beijing People s Liberation Army General Hospital (301 Hospital) Cancer Center, People s Liberation Army General Hospital Cancer Center
解放军总医院肿瘤内一科隶属于内科临床部肿瘤中心，是从事肿瘤个体化综合治疗、免疫治疗、抗体工程和肿瘤靶向治疗的临床和基础研究相结合的综合性机构。肿瘤内一科为"国家临床重点专科军队建设项目"，是国家博士学位授权点，科室现有博士生导师3名，硕士生导师6名，主任医师6名，副主任医师11名，主治医师13名，近五年承接临床试验项目60余项，其中国际多中心30余项，国家、军队、省部级以上课题近20项。肿瘤中心实验室现为全军肿瘤学重点实验室、肿瘤靶向治疗和抗体药物教育部重点实验室、北京抗体药物研发平台、北京市细胞工程和抗体药物重点实验室。
The first department of oncology of People's Liberation Army General Hospital is belonged to the cancer center of department of Internal Medicine Clinical Center. It is a comprehensive organization engaged in individual treatment of cancer, immunotherapy, antibody engineering and combined clinical and basic research of tumor targeted therapy. The first department of oncology is "national clinical key specialist army construction project", which is the national doctoral degree authorization. The department has three doctoral tutors, six master tutors, six chief physicians, 11 deputy chief physicians, 13 attending physicians. Nearly five years, it undertakes more than 60 clinical trials, of which more than 30 international multi-center, and beyond the level of national, military, provincial and ministerial nearly 20. Now, Cancer Center Laboratory is the Key Laboratory of Tumor Oncology, Key Laboratory of Cancer Targeted Therapy and Antibody Drugs, Beijing Antibody Drug Research and Development Platform, Beijing Key Laboratory of Cell Engineering and Antibody Drugs.
北京医院肿瘤科
The oncology department of Beijing Hospital
北京医院是直属国家卫生和计划生育委员会的三级甲等医院具有正副主任医师、正副教授、研究员及相应职称的高级技术人员462人；博士、硕士766人。医院设有临床和医技科室 38个，长期承担着中央领导干部的医疗保健任务及 15000余名司局级以上干部医疗保健任务和80余万参保人员的医疗保险工作。同时，还接待大量京外各地转诊的疑难危重病人。是一家向社会全面开放的医、教、研、防全面发展的现代化综合性医院。北京医院生物治疗中心主要承担肿瘤的发生、发展机制，免疫相关的机制及肿瘤免疫治疗相关研究。
Beijing Hospital directly belongs to the National Health and Family Planning Commission which is the third class A level hospital. The total number of deputy chief physician, associate professor, researcher and the corresponding title of the senior technical staff is 462; the total number of doctorates and masters is 766. The hospital has 38 clinical and medical technical departments, and it long-term commitments to the medical and health care tasks of central leading cadres, more than 15,000 Secretary-level cadres and more than 80 million people who have health insurance. At the same time, it also treats a large number of critically ill patients who are out of Beijing. It is a modern comprehensive hospital which is comprehensive open to the community and develops medical, teaching, research and precaution. Beijing Hospital Biological Treatment Center is mainly responsible for the related research of occurrence, development mechanism, immune-related mechanisms and tumor immunotherapy of tumor.
武汉禾元生物科技股份有限公司
Wuhan Healthgen Biological Technology Co , Ltd
武汉禾元生物科技股份有限公司（股票代码：833101）成立于2006年11月，座落于武汉光谷国家生物产业基地九峰创新基地,是专门从事植物分子医药技术研究与产品开发、知识产权的转让及科技成果的应用、技术出口、货物出口等业务的民营企业；专门从事植物分子农业医药的技术研究与开发、知识产权的转让及科技成果的应用，技术出口，货物出口，代理出口等业务，并于2012年被国家科技部认定的高新科技企业，2013年被武汉市科技局认定为农业型科技企业。
Wuhan Healthgen Biological Technology Co., Ltd. (stock code: 833101) was established in November 2006, is located in Wuhan Optical Valley National Bio-industrial base Jiufeng Innovation Base, is a private enterprises who is specialized in plant molecular medicine technology research and product development, the transfer of intellectual property and the application of scientific achievements, the export of technology, the export of goods and so on; it is specialized in plant molecular agriculture medicine technology research and development, the transfer of intellectual property rights and the application of scientific and technological achievements, technology exports, exports of goods, export agents and so on. In 2012, it is identified high-tech enterprises by the State Ministry of Science and Technology. In 2013 , it is identified as agricultural technology enterprises by the Wuhan Municipal Science and Technology Bureau.
